Marvin Matta Rivera, MD
Hematology & Oncology · Bayamon, PRNPI 1629357488
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 348 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,266, 4.8 times the $678 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in PR, where the typical reported total is $10,882.
Across 348 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AstraZeneca$1K
- AbbVie$639
- PBG Puerto Rico LLC$546
- E.r. Squibb & Sons, L.L.C.$501
- Merck$489
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,45195%
- Education$3675%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 40 | $1,277 |
| AstraZeneca(2 entities) | 50 | $1,094 |
| AbbVie | 28 | $639 |
| PBG Puerto Rico LLC | 30 | $546 |
| E.r. Squibb & Sons, L.L.C. | 22 | $501 |
| Merck | 24 | $489 |
| Genentech USA, Inc. | 24 | $477 |
| Eli Lilly Export S.A. Puerto Rico Branch | 17 | $384 |
| Amgen | 19 | $367 |
| Sanofi | 14 | $312 |
| Bayer Puerto Rico Inc. | 10 | $212 |
| Regeneron Healthcare Solutions, Inc. | 9 | $193 |
| Tempus AI, Inc | 7 | $170 |
| Incyte Corporation | 7 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $84 |
| Bristol Myers Squibb | 4 | $82 |
| Pfizer | 4 | $80 |
| Sobi, Inc | 3 | $72 |
| Seagen Inc. | 3 | $66 |
| Bayer | 3 | $61 |
| Puma Biotechnology, Inc. | 3 | $56 |
| Taiho Oncology, Inc. | 2 | $49 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Exelixis Inc. | 2 | $44 |
| Gilead | 2 | $42 |
| Pfizer Pharmaceuticals LLC | 2 | $33 |
| Pharmaand GmbH | 1 | $26 |
| Tolmar, Inc. | 1 | $26 |
| Clovis Oncology, Inc. | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$7,818 in reported general payments places this provider in the 40th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 40 | $676,693 |
| PromactaEltrombopag Olamine | 30 | $647,637 |
| KineretAnakinra | 12 | $133,406 |
| SprycelDasatinib | 13 | $126,187 |
| XareltoRivaroxaban | 45 | $26,926 |
| Tranexamic Acid | 11 | $2,763 |
| Exemestane | 11 | $2,186 |
| Anastrozole | 87 | $2,181 |
| Cyclophosphamide | 12 | $1,749 |
| SynthroidLevothyroxine Sodium | 23 | $1,233 |
| Letrozole | 31 | $805 |
| Dexamethasone | 24 | $532 |
| Ondansetron Hcl | 16 | $284 |
| Famotidine | 37 | $228 |
| Omeprazole | 29 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $82 | $676,69340 claims |
| NovartisPromacta | $18 | $647,63730 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $501 | $126,18713 claims |
| Johnson & JohnsonXarelto | $1,277 | $26,92645 claims |
| AbbVieSynthroid | $639 | $1,23323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Bayamon
- Yelitza RuizBayamon$28K
- Kenel Fernandez BarbosaBayamon$24K
- Robert HunterBayamon$23K
- Juan Vazquez MedinaBayamon$20K
- Myrna Andino CamachoBayamon$20K
- Elias Sobrino NajulBayamon$17K
- Carlos ChiesaBayamon$17K
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.